Immunopersistence of one or two doses of an Escherichia coli produced bivalent HPV vaccine.

ABSTRACT: Data on the immunopersistence of one- or two-dose regimens of HPV vaccine in women aged 18-45 remains scarce. During 5.5-year follow-up of a Phase 3 clinical trial of Cecolin^® (ClinicalTrials.gov, NCT01735006), blood samples were collected at day 0, month 7 and annually thereafter for neutralizing antibody measurement. Cervical samples were collected for ThinPrep Pap tests and HPV genotyping. At month 66, HPV-16 seropositive rates were 100.0% across all groups (single-dose, two-dose [0-1-month], two-dose [0-6-month], and three-dose). HPV-18 seropositive rates were 63.6%, 93.8%, 84.6% and 98.4%, respectively. Although geometric mean concentrations (GMCs, IU/mL) of neutralizing antibodies in the one- and two-dose groups were lower than in the three-dose group (HPV-16: 10.4, 46.0 a

SUBMITTER: Liao M 

PROVIDER: S-EPMC12820289 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature